Screening, Contraindication, and Antiviral Initiation
We assumed that 91% of those offered screening
would accept it, 90% of those who tested positive would
receive those results, and all patients with prescription drug
insurance coverage (87.6%) and no patients without prescription coverage would be considered for treatment (30,
49). We estimated that 23.1% of patients considered for treatment were contraindicated for modifiable reasons
(such as substance abuse or major depression), 11.5% were
contraindicated for nonmodifiable reasons (such as uncontrolled diabetes or autoimmune disorders), and 8.5% declined treatment (20, 31). After adjustment for these barriers, 40.8% of positive patients offered testing accepted,
were identified, and initiated treatment.